Rodríguez-Vélez Rosángela, Ortiz-Rivera Oscar J, Bower Bruce, Gorowski Krystyna, Windemuth Andreas, Villagra David, Kocherla Mohan, Seip Richard L, D'Agostino Darrin, Vergara Cunegundo, Ruaño Gualberto, Duconge Jorge
University of Puerto Rico School of Pharmacy, San Juan Puerto Rico.
P R Health Sci J. 2010 Dec;29(4):402-8.
A case to illustrate the utility of genetic screening in warfarin (Coumadin) management is reported. A 45 year-old woman of Puerto Rican ancestry was admitted to the emergency room twice within one month with chest pain. She was diagnosed with congestive heart failure, which was stabilized both times. At her second release, warfarin therapy was initiated at 5 mg/ day to prevent thrombus formation and was lowered to 3.75 mg/day at day 7 by her primary physician. International Normalized Ratio (INR) test results in the follow-up period at days 1, 7, and 10 of warfarin therapy were 4.5, 6.5, and 7.3, respectively-far in excess of the therapeutic range, despite the lower dosage in effect from day 7 onward. The patient achieved target INR over the next 43 days after downward adjustment of the dose to a dose of 1.5 mg/day by trial and error. DNA-typing specific for the CYP2C9*2,*3,*4,*5,6 alleles and seven variants in the VKORC1 gene, including the VKORC1-1639 G > A polymorphism, revealed the presence of combinatorial CYP2C92/*3 and VKORC1-1639 G/A genotypes in this patient. Entering the patient's demographic and genotype status data into independent algorithms available in the public domain to predict effective warfarin dose yielded predicted doses which ranged from 1.5 to 1.8 mg/day. Notably, the prediction of 1.5 mg/day, which was generated by the online resource www.warfarindosing.org, coincided with the patient's actual effective warfarin dose. We conclude that the rapid rise in INR observed upon the initiation of warfarin therapy and the final effective warfarin dose of 1.5 mg/day, are attributable in some part to the presence of two minor alleles in CYP2C9, which together significantly reduce warfarin metabolism. Warfarin genotyping can therefore inform the clinician of the predicted effective warfarin dose. The results highlight the potential for warfarin genetic testing to improve patient care.
报告了一例说明基因筛查在华法林(香豆素)治疗管理中的作用的病例。一名45岁的波多黎各裔女性在一个月内两次因胸痛被送往急诊室。她被诊断为充血性心力衰竭,两次病情均得到稳定。在她第二次出院时,开始使用华法林治疗,剂量为5毫克/天,以预防血栓形成,7天时她的主治医生将剂量降至3.75毫克/天。在华法林治疗的第1天、第7天和第10天的随访期内,国际标准化比值(INR)测试结果分别为4.5、6.5和7.3,尽管从第7天起剂量降低,但仍远超过治疗范围。在通过反复试验将剂量下调至1.5毫克/天后的接下来43天里,患者的INR达到了目标值。对CYP2C9*2、*3、*4、*5、6等位基因以及VKORC1基因中的七个变体(包括VKORC1 - 1639 G > A多态性)进行的DNA分型显示,该患者存在组合的CYP2C92/*3和VKORC1 - 1639 G/A基因型。将患者的人口统计学和基因型状态数据输入公共领域可用的独立算法中以预测有效的华法林剂量,得出的预测剂量范围为1.5至1.8毫克/天。值得注意的是,在线资源www.warfarindosing.org生成的1.5毫克/天的预测值与患者实际有效的华法林剂量相符。我们得出结论,华法林治疗开始时观察到的INR快速上升以及最终1.5毫克/天的有效华法林剂量,在一定程度上归因于CYP2C9中两个次要等位基因的存在,这两个等位基因共同显著降低了华法林的代谢。因此,华法林基因分型可以告知临床医生预测的有效华法林剂量。结果突出了华法林基因检测改善患者护理的潜力。